Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Authors
Keywords
-
Journal
mAbs
Volume 6, Issue 5, Pages 1133-1144
Publisher
Informa UK Limited
Online
2014-06-24
DOI
10.4161/mabs.29670
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Complement and Its Receptors: New Insights into Human Disease
- (2014) V. Michael Holers Annual Review of Immunology
- A Novel Non-Synonymous Polymorphism (p.Arg240His) in C4b-Binding Protein Is Associated with Atypical Hemolytic Uremic Syndrome and Leads to Impaired Alternative Pathway Cofactor Activity
- (2014) Anna M. Blom et al. JOURNAL OF IMMUNOLOGY
- Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between Fc RI and Fc RIV
- (2014) M. A. Otten et al. JOURNAL OF IMMUNOLOGY
- Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
- (2014) C. A. Diebolder et al. SCIENCE
- An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels
- (2013) Thies Rösner et al. BRITISH JOURNAL OF HAEMATOLOGY
- Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells
- (2013) S. Horl et al. HAEMATOLOGICA
- Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
- (2013) S Hörl et al. LEUKEMIA
- GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present
- (2013) Delila J. Kern et al. LEUKEMIA & LYMPHOMA
- The role of complement in mAb-based therapies of cancer
- (2013) Ronald P. Taylor et al. METHODS
- Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
- (2013) Srinivas Mamidi et al. Molecular Oncology
- Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma
- (2012) Bridget Charbonneau et al. AMERICAN JOURNAL OF HEMATOLOGY
- Boosting antibody therapy with complement
- (2012) P. Boross et al. BLOOD
- A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer
- (2012) M. Elvington et al. BLOOD
- Anti-Tumor Monoclonal Antibodies in Conjunction with β-Glucans: A Novel Anti- Cancer Immunotherapy
- (2012) D. Xiang et al. CURRENT MEDICINAL CHEMISTRY
- Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy
- (2012) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
- (2012) F. J. Beurskens et al. JOURNAL OF IMMUNOLOGY
- Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement
- (2012) Nisar A. Baig et al. LEUKEMIA & LYMPHOMA
- Transient Removal of CD46 Is Safe and Increases B-cell Depletion by Rituximab in CD46 Transgenic Mice and Macaques
- (2012) Ines Beyer et al. MOLECULAR THERAPY
- Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis
- (2011) W. Hu et al. CANCER RESEARCH
- rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
- (2011) X. Ge et al. CLINICAL CANCER RESEARCH
- The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
- (2011) P. Boross et al. HAEMATOLOGICA
- Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach
- (2011) Masami Kadowaki et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
- (2011) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
- (2011) Nigel M. Stapleton et al. Nature Communications
- Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
- (2010) S. A. Beers et al. BLOOD
- Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro
- (2010) N. Geis et al. CURRENT CANCER DRUG TARGETS
- Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia
- (2010) Wei Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
- (2010) Gregory L. Moore et al. mAbs
- Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma
- (2009) Abraham Klepfish et al. Annals of the New York Academy of Sciences
- Complement in antibody therapy: friend or foe?
- (2009) M. Introna et al. BLOOD
- Complement: help or hindrance?
- (2009) S. A. Beers et al. BLOOD
- Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model
- (2009) S.-Y. Wang et al. BLOOD
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35)
- (2009) Dong Liu et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging
- (2009) Arnout F. Gerritsen et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Complement in human diseases: Lessons from complement deficiencies
- (2009) Marina Botto et al. MOLECULAR IMMUNOLOGY
- Therapeutic potential of complement modulation
- (2009) Eric Wagner et al. NATURE REVIEWS DRUG DISCOVERY
- C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress
- (2009) Massimo Cugno et al. TRENDS IN MOLECULAR MEDICINE
- Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
- (2008) S. A. Beers et al. BLOOD
- Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV
- (2008) V. Minard-Colin et al. BLOOD
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
- (2008) A. Natsume et al. CANCER RESEARCH
- Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies
- (2008) M. Dechant et al. CANCER RESEARCH
- A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
- (2008) E. Racila et al. CLINICAL CANCER RESEARCH
- The possible role of factor H in colon cancer resistance to complement attack
- (2008) Ewa Wilczek et al. INTERNATIONAL JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started